Pfizer Files Lawsuit Against Metsera and Novo Nordisk Over Merger Agreement
In a recent development, Pfizer has taken legal action against Metsera and Novo Nordisk, alleging that Metsera violated its obligations under the merger agreement by deeming Novo’s $8.5 billion bid as a superior offer. Pfizer has sought a temporary restraining order from a Delaware court to prevent Metsera from terminating the agreement. The details of the lawsuit are not yet available in the court’s electronic filing system.
Metsera has given Pfizer until Tuesday to increase its offer, prompting Pfizer to take legal action. The lawsuit claims that Novo’s bid is an unlawful attempt by a dominant market player to circumvent antitrust scrutiny, posing significant regulatory risks.
This legal dispute arises as Pfizer has received early antitrust clearance from the U.S. Federal Trade Commission for its proposed $7.3 billion acquisition of Metsera. The clearance was granted more than a week ahead of the deadline under the Hart-Scott-Rodino Act.
Pfizer’s interest in acquiring Metsera stems from its desire to enter the booming obesity market, projected to reach $150 billion by the early 2030s. With no current weight-loss drugs in its portfolio, Pfizer sees the acquisition as a strategic move to offset declining revenue from COVID-related products and impending patent expirations.
On the other hand, Novo Nordisk, known for its drugs Wegovy and Ozempic, aims to regain market share lost to competitors like Eli Lilly. Novo’s bid for Metsera is seen as a strategic move to strengthen its position in the obesity treatment market.
Metsera’s pipeline includes promising GLP-1 and amylin-based therapies that analysts believe could generate up to $5 billion in peak sales. The company’s innovative treatments have attracted the attention of major players in the pharmaceutical industry.
Both Metsera and Novo Nordisk have yet to respond to requests for comment from Reuters, indicating the sensitivity of the situation. The outcome of Pfizer’s lawsuit against Metsera and Novo could have significant implications for the future of the companies involved.
In conclusion, the legal battle between Pfizer, Metsera, and Novo Nordisk highlights the competitive nature of the pharmaceutical industry. As the companies vie for dominance in the lucrative obesity market, the outcome of this dispute will shape the landscape of the industry for years to come. Stay tuned for updates on this developing story.
By Kamal Choudhury, Christy Santhosh, and Siddhi Mahatole in Bengaluru; Edited by Shilpi Majumdar and Anil D’Silva
